# Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

> **NCT04467983** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Hospital for Special Surgery, New York** · enrollment: 70 (estimated)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** Denosumab Injection
- **DRUG:** Abaloparatide

## Key facts

- **NCT ID:** NCT04467983
- **Lead sponsor:** Hospital for Special Surgery, New York
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04467983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04467983, "Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04467983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*